Skip
UTPhysicians logoUT Physicians - a part of UTHealth
By invitation only, a COVID-19 vaccine is currently available to priority at-risk patients. Learn more.

888-4UT-DOCS | 888-488-3627

  • About Us
    About UT Physicians Careers Contact Us News Health Programs/Services Patient Stories Videos
  • Find a Provider / Clinic
    Search By Specialty Search Providers Search By Name Search By Location
  • Patient Information
    About your Visit Billing Information Clinical Trials Insurance Refer a patient Make an Appointment International Patients Medical Records Legal Billing Records
  • Health Programs/Services
  • Make an Appointment
  • Pay My Bill
  • MyUTP Portal
  • Careers

Physicians investigate whether magnetic seizure therapy can treat bipolar depression

Written by: Amy Laukka | Updated: November 20, 2020
Find a Physician / Clinic
  • Search By Specialty
  • Search Providers
  • Search By Name
  • Search By Location
Salih Selek, MD, conducted magnetic seizure therapy (MST) in a clinical trial investigating whether the therapy can help relieve treatment-resistant depression in bipolar patients. (Photo by Maricruz Kwon/UTHealth)

Salih Selek, MD, conducted magnetic seizure therapy (MST) in a clinical trial investigating whether the therapy can help relieve treatment-resistant depression in bipolar patients. (Photo by Maricruz Kwon/UTHealth)

Photo of Jair Soares, MD, PhD, and Salih Selek, MD

Salih Selek, MD, and Jair Soares, MD, PhD

Researchers are assessing whether magnetic seizure therapy (MST) can help relieve treatment-resistant depression in bipolar patients in a clinical trial led by The University of Texas Health Science Center at Houston (UTHealth).

The trial, which takes place at UTHealth Harris County Psychiatric Center (UTHealth HCPC), will study whether the novel treatment can deliver the same results as the standard of care, electroconvulsive therapy (ECT), without the potential cognitive side effects.

During ECT, small electric currents are passed through the brain, intentionally triggering a brief seizure. The seizures cause changes in brain chemistry that can reverse symptoms of certain mental health conditions.

“ECT is still considered the gold standard for treatment-resistant depression, but it can have negative side effects in some patients, including memory problems,” said Salih Selek, MD, professor in the Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences at McGovern Medical School at UTHealth and director of the UTHealth Refractory Mood Disorders Program at UTHealth HCPC. “In this trial, we’ll use a different machine that uses magnetic waves, not electricity, to induce seizures. So instead of sending an electric signal to the brain, it sends magnetic waves to the frontal parietal lobe of the brain, which helps control emotions.” Selek is also a psychiatrist with UT Physicians, the clinical practice of McGovern Medical School.

The magnetic pulses can focus the stimulation to a specific area of brain tissue, since they do not have to go through the scalp and skull to reach the brain as in ECT.

Bipolar disorder is a neurobiological brain disorder that affects approximately 2.3 million Americans today. Many patients with bipolar disorder either don’t respond at all or don’t respond well to antidepressant medication, Selek said.

“Depressive episodes are common during the course of the bipolar disorder, and now the pandemic is causing increased stress and depression for many,” Selek said. “Sometimes depression in bipolar patients can lead to suicide attempts, so it is critically important for us to know the best way to treat bipolar depression in patients who’ve already tried all other treatments.”

“We are very excited that UTHealth will start to test the potential role of this new technology as a treatment for severe, treatment-resistant bipolar depression,” said Jair Soares, MD, PhD, the Pat R. Rutherford, Jr. Chair in Psychiatry in the Faillace Department of Psychiatry and Behavioral Sciences.  “Bipolar depression is an important area where new treatments are really needed. It’s good timing for a study like this, given the current stressors caused by COVID-19.” Soares is also the executive director of UTHealth HCPC.

Researchers are looking for 60 participants who will be randomized to ETC or MST. Patients must be over 22 years of age. Both arms of the treatment are done under anesthesia and will be completed in up to 15 sessions over five weeks.

For more information, visit ClinicalTrials.gov or contact 713-741-5915.


Share

All Articles
  • Cardiothoracic & Vascular Surgery
  • Children's Health Stories
  • Coronavirus
  • Coronavirus Español
  • COVID-19 Patient Resources
  • Ear, Nose, and Throat Stories
  • Epilepsy
  • Featured
  • Heart Care
  • In the Media
  • In the Media Español
  • News
  • Orthopedics
  • Patient Stories
  • Pediatric Surgery
  • UTHealth COVID-19 Research
  • UTHealth Research
  • Women's Health Stories

UT Physicians A part of UTHealth

UT Professional Building
6410 Fannin Street | Houston, Texas 77030
888-4UT-DOCS (888-488-3627)

UT Physicians - facebook UT Physicians - instagram UT Physicians - twitter UT Physicians - linkedin UT Physicians - youtube

UT PHYSICIANS APP NOW AVAILABLE FOR DOWNLOAD

Downlaod the UT Physicians App on the Apple Store
Downlaod the UT Physicians App on Google Play

AN OFFICIAL ORTHOPEDIC AND SPORTS MEDICINE PROVIDER FOR

Houston Dynamo Logo
Houston Dash Logo

THE CLINICAL PRACTICE OF

McGovern Medical School at UTHealth
Contact / Feedback | Report Error | Patient Privacy | Web File Viewing | Site Policies | Employee Links

Copyright © 2018 to Present – The University of Texas Health Science Center at Houston (UTHealth)